유전성 암검사 시장 규모, 점유율, 동향 분석 리포트 : 암별, 기술별, 검사 유형별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Hereditary Cancer Testing Market Growth & Trends:

The global hereditary cancer testing market size is expected to reach of USD 9,452.9 million by 2030, and is projected to grow at a CAGR of 12.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is accelerating, due to government support and healthcare funding and growth of direct-to-consumer (DTC) genetic testing platforms. Hereditary cancer accounts overall to 10% and remaining 90% is sporadic cancer. There arises a need to address this growing demand of hereditary cancer which may be possible by government initiatives and funding to meet the healthcare demand. Government initiatives and funding aim at cancer prevention and genetic research significantly drive the hereditary cancer testing market.

Many countries have introduced policies that promote genetic testing as part of cancer risk assessment programs, often providing financial support for testing costs. For example, the National Comprehensive Cancer Network (NCCN), in January 2025, released a new resource designed to provide individuals with the most up-to-date recommendations on hereditary and familial cancer risks. These guidelines focus on hereditary breast, ovarian, pancreatic and prostate cancer which is available also through and app. It offers clear, easy-to-understand guidance on how to assess and test for inherited genetic mutations that may increase the risk of cancer. The information is available in a straightforward and accessible way for better comprehension.

Regulatory approvals for hereditary cancer testing ensures that genetic tests used to assess cancer risk meet rigorous standards for accuracy, safety, and reliability. The FDA classifies these tests as medical devices, and they must undergo thorough evaluation before receiving approval for market use. U.S. Food and Drug Administration (FDA) in September 2023, granted its first-ever marketing authorization for a DNA test designed to assess the genetic predisposition to multiple types of cancer. This groundbreaking approval can access multiple variant genes through next generation sequencing (NGS) which are linked to an increased risk of several cancers, including breast, ovarian, and colorectal cancers to provide insights with sensitivity, speed and accuracy. By identifying these inherited genetic mutations, the test provides individuals with valuable information to guide early detection, preventive measures, and personalized treatment plans. This approval marks a significant milestone in the field of genetic testing and cancer prevention, empowering individuals to take proactive steps toward managing their health.

Recognizing the potential of genetic testing in revolutionizing healthcare, government launches several initiatives aimed at integrating genetic services into the public health infrastructure. One significant stride taken by National Cancer Institute that awarded USD 3.2 million grant to researchers at Georgetown University's Lombardi Comprehensive Cancer Center and the Rutgers Cancer Institute of New Jersey. This funding supports a five-year study enrolling 428 Black cancer patients who meet national guidelines for hereditary cancer testing into a randomized controlled trial and will evaluate the impact of these interventions on genetic education engagement, testing uptake, informed decision-making, and psychosocial outcomes. By addressing barriers to genetic testing and incorporating community input, the research aimed at improving access to screening, and medical management of cancers, ultimately advancing health equity in oncology care.

The market has been witnessing activity of the key players such as Myriad Genetics, Inc., Bio-Rad Laboratories, F. HOFFMANN-LA ROCHE LTD and Illumina, Inc. these players are actively engaged in seeking product approvals from USFDA to meet the need of global customers. For instance, in June 2024, Myriad Genetics, Inc, announced its ongoing innovations: MyChoice CDx HRD and BRACAnalysis CDx Germline Companion Diagnostic Tests for enhancing its product portfolio through research collaborations. Additionally, Myriad has initiated multiple research collaborations to investigate the potential of MRD in various cancers. Furthermore, developments in precision medicine online screening tools for cancer enable patient education for improved outcomes. For instance, in January 2025, Myriad Genetics, Inc, announced a study showing that patients were more likely to complete hereditary cancer testing when using an online screening tool combined with genetic education. This approach highlights the importance of digital tools and education in increasing engagement and participation in genetic testing for cancer risk assessment.

Thus, technological advancements in genetic testing, growing government initiatives and funding support and accelerated regulatory approvals are boosting the market growth for early detection and disease prevention.

Hereditary Cancer Testing Market Report Highlights:

• Based on cancer, breast cancer accounted for largest revenue share of 12.45% in 2024. The hereditary breast cancer testing market is expanding due to advancements in next-generation sequencing (NGS) and artificial intelligence (AI), enabling comprehensive risk assessments. Increased awareness, government initiatives, and expanded insurance coverage further drive adoption. These innovations facilitate early detection and personalized prevention strategies, enhancing patient outcomes.
• Based on technology, molecular testing dominated the market and accounted for the largest share of 56.36% in 2024.The molecular testing segment in the hereditary cancer testing market is expanding due to rising prevalence of cancer, advancements in next-generation and quick genetic analysis. These technologies enhance diagnostic accuracy and facilitate personalized treatment strategies. Additionally, increased awareness and insurance coverage are driving adoption.
• Based on test type, in 2024, predictive genetic testing emerged as the dominant segment in the hereditary cancer testing market, capturing 66.49% of the share. The increasing prevalence of genetic disorders and a growing emphasis on preventive healthcare further drive the adoption of predictive genetic tests.
• Based on end use, hospitals dominated the end-use segments with the largest market share of 55.11% in 2024 and were the fastest growing among the other segments over the period. Hospitals in collaboration with research universities are boosting the growth for this market.
• North America dominated the global market due to the presence of a large number of major market players, advancements in next-generation sequencing (NGS), increasing awareness of genetic risks, and expanded insurance coverage.
• Asia Pacific region is expected to witness fastest growth with a CAGR of 14.3% from 2025 to 2030, due to expansion by key players with innovative technologies coupled with accelerated diagnostic research capabilities.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Cancer
  • 1.2.2. Technology
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Cancer outlook
  • 2.2.2. Technology outlook
  • 2.2.3. Test Type outlook
  • 2.2.4. End Use outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Hereditary Cancer Testing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Technological advancements of genetic testing in cancer detection
    • 3.2.1.2. Integration with precision medicine
    • 3.2.1.3. Growing awareness through public and government initiatives
    • 3.2.1.4. Rising prevalence of cancer
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High costs and limited insurance coverage
• 3.3. Hereditary Cancer Testing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Hereditary Cancer Testing Market: Cancer Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Hereditary Cancer Testing Market: Cancer Movement Analysis
• 4.3. Hereditary Cancer Testing Market Size & Trend Analysis, by cancer, 2018 to 2030 (USD Million)
• 4.4. Hereditary Cancer Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Lung Cancer
  • 4.5.1. Lung Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Breast Cancer
  • 4.6.1. Breast Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Colorectal Cancer
  • 4.7.1. Colorectal Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Cervical Cancer
  • 4.8.1. Cervical Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Ovarian Cancer
  • 4.9.1. Ovarian Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.10. Prostate Cancer
  • 4.10.1. Prostate Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.11. Stomach/Gastric Cancer
  • 4.11.1. Stomach/Gastric Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.12. Melanoma
  • 4.12.1. Melanoma Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.13. Sarcoma
  • 4.13.1. Sarcoma Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.14. Uterine Cancer
  • 4.14.1. Uterine Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.15. Pancreatic Cancer
  • 4.15.1. Pancreatic Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.16. Others
  • 4.16.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Hereditary Cancer Testing Market: Technology Estimates & Trend Analysis

• 5.1. Technology Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Hereditary Cancer Testing Market by Technology Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Cytogenetic
  • 5.5.1. Cytogenetic Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Biochemical
  • 5.6.1. Biochemical Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Molecular Testing
  • 5.7.1. Molecular Testing Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Test type Market: Test Type Estimates & Trend Analysis

• 6.1. Test type Market Share, 2024 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Test type Market by Capacity Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. Predictive Testing
  • 6.5.1. Predictive Testing Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Diagnostic Testing
  • 6.6.1. Diagnostic Testing Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. End Use Market: End Use Estimates & Trend Analysis

• 7.1. End Use Market Share, 2024 & 2030
• 7.2. Segment Dashboard
• 7.3. Global End Use Market by End Use Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 7.5. Diagnostic Centers
  • 7.5.1. Diagnostic Centers Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Hospitals
  • 7.6.1. Hospitals Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Clinics
  • 7.7.1. Clinics Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Hereditary Cancer Testing Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.5. North America
  • 8.5.1. North America: SWOT Analysis
  • 8.5.2. U.S.
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/Reimbursement
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. Canada
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/Reimbursement
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Mexico
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/Reimbursement
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Europe
  • 8.6.1. Europe: SWOT Analysis
  • 8.6.2. UK
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/Reimbursement
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.3. Germany
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/Reimbursement
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.4. France
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework/Reimbursement
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.5. Italy
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework/Reimbursement
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.6. Spain
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework/Reimbursement
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.7. Norway
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory framework/Reimbursement
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.8. Sweden
    • 8.6.8.1. Key country dynamics
    • 8.6.8.2. Regulatory framework/Reimbursement
    • 8.6.8.3. Competitive scenario
    • 8.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.9. Denmark
    • 8.6.9.1. Key country dynamics
    • 8.6.9.2. Regulatory framework/Reimbursement
    • 8.6.9.3. Competitive scenario
    • 8.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. Asia Pacific
  • 8.7.1. Asia Pacific: SWOT Analysis
  • 8.7.2. Japan
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/Reimbursement
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. China
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/Reimbursement
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. India
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/Reimbursement
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.5. Australia
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework/Reimbursement
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.6. South Korea
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory framework/Reimbursement
    • 8.7.6.3. Competitive scenario
    • 8.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.7. Thailand
    • 8.7.7.1. Key country dynamics
    • 8.7.7.2. Regulatory framework/Reimbursement
    • 8.7.7.3. Competitive scenario
    • 8.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.8. Latin America
  • 8.8.1. Latin America: SWOT Analysis
  • 8.8.2. Brazil
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework/Reimbursement
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.3. Argentina
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Regulatory framework/Reimbursement
    • 8.8.3.3. Competitive scenario
    • 8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.9. MEA
  • 8.9.1. MEA: SWOT Analysis
  • 8.9.2. South Africa
    • 8.9.2.1. Key country dynamics
    • 8.9.2.2. Regulatory framework/Reimbursement
    • 8.9.2.3. Competitive scenario
    • 8.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.3. Saudi Arabia
    • 8.9.3.1. Key country dynamics
    • 8.9.3.2. Regulatory framework/Reimbursement
    • 8.9.3.3. Competitive scenario
    • 8.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.4. UAE
    • 8.9.4.1. Key country dynamics
    • 8.9.4.2. Regulatory framework/Reimbursement
    • 8.9.4.3. Competitive scenario
    • 8.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.5. Kuwait
    • 8.9.5.1. Key country dynamics
    • 8.9.5.2. Regulatory framework
    • 8.9.5.3. Competitive scenario
    • 8.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. List of key distributors and channel partners
  • 9.3.2. Key customers
  • 9.3.3. Key company market share analysis, 2024
  • 9.3.4. Myriad Genetics, Inc.
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Services benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Invitae Corporation
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Services benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Bio-Rad Laboratories
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Services benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. CSL Ltd
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Services benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Qiagen NV
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Services benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Danaher Corporation
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Services benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Thermo Fisher Scientific
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Services benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. Abbott Laboratories
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Services benchmarking
    • 9.3.11.4. Strategic initiatives
  • 9.3.12. EUROFINS SCIENTIFIC
    • 9.3.12.1. Company overview
    • 9.3.12.2. Financial performance
    • 9.3.12.3. Services benchmarking
    • 9.3.12.4. Strategic initiatives
  • 9.3.13. F. HOFFMANN-LA ROCHE LTD
    • 9.3.13.1. Company overview
    • 9.3.13.2. Financial performance
    • 9.3.13.3. Services benchmarking
    • 9.3.13.4. Strategic initiatives
  • 9.3.14. Illumina, Inc.
    • 9.3.14.1. Company overview
    • 9.3.14.2. Financial performance
    • 9.3.14.3. Services benchmarking
    • 9.3.14.4. Strategic initiatives